Back to results
US 2022/0177580 A1Published application
Modulating antibody effector functions
AssigneeAmgen Inc.
InventorsSCOTT THOMAS KUHNS, RUPA PADAKI, QINGCHUN ZHANG, WILLIAM S BRETZLAFF
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeAmgen Inc.
InventorsSCOTT THOMAS KUHNS, RUPA PADAKI, QINGCHUN ZHANG, WILLIAM S BRETZLAFF
Estimating the term…
Provided herein are methods of modulating Fc gamma Receptor (FcγR)-mediated cytotoxicity of an antibody composition. In exemplary embodiments, the method comprises (1) increasing or decreasing the amount of terminal β-galactose at the N-297 glycosylation site of panitumumab, or increasing or decreasing the amount of panitumumab molecules that comprise G1, G1a, G1b and/or G2 galactosylated glycan at the N-297 site, (2) increasing or decreasing the amount of panitumumab molecules that comprise fucosylated glycan at the N-297 site, or increasing or decreasing the amount of panitumumab molecules that comprise afucosylated glycan at the N-297 site, and (3) increasing or decreasing the amount of panitumumab molecules that comprise a high-mannose glycan at the N-297 site.
A method of modulating Fc gamma Receptor (FcγR)-mediated cytotoxicity of panitumumab, comprising increasing or decreasing the amount of terminal β-galactose at the N-297 glycosylation site of panitumumab, or increasing or decreasing the amount of panitumumab molecules that comprise G1, G1a, G1b and/or G2 galactosylated glycan at the N-297 site.
A method of modulating Fc gamma Receptor (FcγR)-mediated cytotoxicity of panitumumab, comprising increasing or decreasing the amount of panitumumab molecules that comprise fucosylated glycan at the N-297 site, or increasing or decreasing the amount of panitumumab molecules that comprise afucosylated glycan at the N-297 site.
A method of modulating Fc gamma Receptor (FcγR)-mediated cytotoxicity of panitumumab, comprising increasing or decreasing the amount of panitumumab molecules that comprise a high-mannose glycan at the N-297 site.
A method of matching the Fc gamma Receptor (FcγR)-mediated cytotoxicity of a panitumumab sample to a reference value, comprising:
A method of matching the Fc gamma Receptor (FcγR)-mediated cytotoxicity of a panitumumab sample to a reference value, comprising:
A method of matching the Fc gamma Receptor (FcγR)-mediated cytotoxicity of a panitumumab sample to a reference value, comprising:
Dependencies are inferred from the claim text.